Lung cancer vaccine tested on a UK patient in trial

Researchers leading the trial said the treatment could improve survival rates among people with the disease, with hopes that it could eventually become the standard of care worldwide.

Known as BNT116 and made by BioNTech, the vaccine is designed to treat non-small cell lung cancer (NSCLC), the most common form of the disease.

It utilises messenger RNA (mRNA), similar to Covid-19 vaccines, and works by presenting the immune system with tumour markers from NSCLC to prime the body to fight cancer cells expressing these markers.

An injection of a BioNTech mRNA cancer immunotherapy for non-small cell lung cancer (NSCLC). (Image: PA)

It is hoped the jab will bolster a person’s immune response to cancer while leaving healthy cells untouched, unlike chemotherapy.

Lung cancer vaccine tested in UK for first time

Professor Siow Ming Lee, a consultant medical oncologist at University College London Hospitals NHS Foundation Trust (UCLH) – which is leading the trial in the UK, told the PA news agency: “This technology has moved on incredibly fast.

“It’s simple to deliver, and you can select specific antigens in the cancer cell, and then you target them.”

The phase one clinical trial is the first in human study of BNT116, which will be given to lung cancer patients alongside standard immunotherapy.

Patient Janusz Racz receives an injection of a BioNTech mRNA cancer immunotherapy for non-small cell lung cancer (NSCLC) (Image: PA)

“Immunotherapy has made a big progress, especially in lung cancer,” Prof Lee added. “But it still doesn’t treat all lung cancer patients successfully.

“We know it’s well tolerated for our Covid vaccine patients, so we hope it will be well tolerated for cancer patients.

“This technology is the next big phase of cancer treatment. We’ve been through chemotherapy. We’ve been through the standard immunotherapy treatment for some lung cancer patients.

“We’ve got personalised treatments using EGFR (epidermal growth factor receptor). But now we just want to add on another additional immune approach attack, and we hope it’s a success.”

Mr Racz, a 67-year-old scientist who moved from Poland to London a decade ago, was diagnosed with lung cancer in May (Image: PA)

The trial will take place across 34 research sites in seven countries, with six located in England and Wales.

Overall, it is hoped about 130 lung cancer patients will be enrolled, 20 of whom will be based in the UK.

Janusz Racz, 67, who lives in London, is the first person to have the vaccine in the UK.

He was diagnosed with lung cancer in May and soon after started chemotherapy and radiotherapy, which was given concurrently.

The scientist, who specialises in artificial intelligence (AI), told PA that the main reason he wanted to take part in the trial is his profession.

“The main reason is that I am a scientist too, and I understand that the progress of science – especially in medicine – lies in people agreeing to be involved in such investigations,” Mr Racz said.

He added: “And also, I can be a part of the team that can provide proof of concept for this new methodology, and the faster it would be implemented across the world, more people will be saved.”

Mr Racz received six consecutive injections given five minutes apart over a half-hour period at the National Institute for Health Research UCLH Clinical Research Facility on Tuesday.

RECOMMENDED READING

Lung cancer vaccine: How does it work?

Each jab contained different RNA strands. He will get the vaccine every week for six consecutive weeks, and then every three weeks for a total of 54 weeks.

Prof Lee added: “We hope adding this additional treatment will stop the cancer coming back because a lot of time for lung cancer patients, even after surgery and radiation, it does come back.

“We know the standard immunotherapy after concurrent chemoradiation can improve survival significantly.”